Early during the pandemic, there was some concern about their use for treating COVID-19 symptoms because of a supposed increased risk of cardiovascular events (Little, 2020), as well as the possibility to exacerbate COVID-19 symptoms, via upregulation of angiotensin-converting enzyme 2 (ACE2) receptors in the lungs, arteries, heart, kidney, and intestines (Kuba et al., 2005). The gene discussed is ACE2; the disease is COVID-19.